title: Prognostic implications of EGFR and HER-2 alteration assessed by immunohistochemistry and silver in situ hybridization in gastric cancer patients following curative resection.
abstract: BACKGROUND
  The aim of this study was to use immunohistochemistry (IHC) and silver in situ hybridization (SISH) to evaluate alterations in EGFR and HER2 in gastric cancer in order to determine the relationship with prognosis in gastric cancer patients following curative resection.
  
  
  METHODS
  In this study, we analyzed EGFR and HER-2 status by IHC and SISH in 254 stage I-III gastric cancer patients who underwent curative surgery.
  
  
  RESULTS
  Thirteen cases (2.48 %) showed EGFR alteration by IHC or SISH. EGFR alteration was associated with older age (P = 0.021), intestinal type (P = 0.040) and higher stage disease (P < 0.001). The patients with operable state gastric cancer who had EGFR alteration had an unfavorable prognosis, and multivariate analysis confirmed that EGFR alteration was an independent unfavorable prognostic factor. Twenty-seven cases (10.6 %) showed HER-2 alteration by IHC or SISH. HER-2 alteration was associated with older age (P = 0.006), well or moderately differentiated histology (P < 0.001) and intestinal type (P = 0.002).
  
  
  CONCLUSIONS
  HER-2 alteration is not an independent prognostic factor for curatively resectable gastric cancer. We observed EGFR alteration in a subset of cases with operable state gastric cancer and determined that it was associated with an unfavorable prognosis.
authors: Department of Internal Medicine, GangNeung Asan Medical Center, University of Ulsan College of Medicine, Gangneung, Korea.
authors: Ho Suk
authors: HS
authors: Oh
authors: Dae-Woon
authors: DW
authors: Eom
authors: Gil Hyun
authors: GH
authors: Kang
authors: Yong Chel
authors: YC
authors: Ahn
authors: Sang Jin
authors: SJ
authors: Lee
authors: Ji-Hoon
authors: JH
authors: Kim
authors: Hyuk Jai
authors: HJ
authors: Jang
authors: Eun Jung
authors: EJ
authors: Kim
authors: Kwang Hoon
authors: KH
authors: Oh
authors: Heui June
authors: HJ
authors: Ahn
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D066246:ErbB Receptors / Q000378:metabolism*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D017403:In Situ Hybridization / Q000379:methods; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D012834:Silver; D013274:Stomach Neoplasms / Q000473:pathology* / Q000601:surgery
chemical_list: D066246:ErbB Receptors; D018719:Erb-b2 Receptor Tyrosine Kinases; D012834:Silver
references: Lancet. 2010 Aug 28;376(9742):687-97
references: 20728210
references: Hum Pathol. 2007 Sep;38(9):1386-93
references: 17555797
references: J Clin Oncol. 2005 Apr 10;23(11):2445-59
references: 15753456
references: Virchows Arch. 2004 Apr;444(4):324-31
references: 14991403
references: J Clin Oncol. 2003 Jul 15;21(14):2787-99
references: 12860957
references: Gan To Kagaku Ryoho. 2010 Aug;37(8):1489-96
references: 20716873
references: Am J Pathol. 1997 Sep;151(3):761-8
references: 9284825
references: Ann Oncol. 2005 Feb;16(2):273-8
references: 15668283
references: Histol Histopathol. 2000 Apr;15(2):455-62
references: 10809364
references: Hum Pathol. 2012 Mar;43(3):413-22
references: 21855114
references: Ann Oncol. 2002 Nov;13(11):1779-85
references: 12419751
references: Eur J Surg Oncol. 2005 Jun;31(5):453-60
references: 15922879
references: Dig Dis Sci. 2006 Aug;51(8):1371-9
references: 16868827
references: Curr Opin Oncol. 2009 Jul;21(4):381-5
references: 19412098
references: Recent Results Cancer Res. 2003;162:115-32
references: 12790326
references: World J Surg. 2007 Jul;31(7):1458-68
references: 17516110
references: Ann Thorac Surg. 1998 Dec;66(6):1894-902
references: 9930465
references: J Natl Cancer Inst. 2007 Apr 18;99(8):601-7
references: 17440161
references: Br J Surg. 2005 Sep;92(9):1099-102
references: 15931657
references: Ann Surg Oncol. 2003 Apr;10(3):234-41
references: 12679307
references: Br J Cancer. 2009 Mar 10;100(5):732-8
references: 19259093
references: Nature. 2007 Mar 8;446(7132):153-8
references: 17344846
references: Mod Pathol. 2004 May;17(5):579-87
references: 15073595
references: Eur J Cancer. 2001 Sep;37 Suppl 4:S9-15
references: 11597399
references: Ann Oncol. 2012 Oct;23(10):2656-2662
references: 22689179
references: Cancer Chemother Pharmacol. 2007 May;59(6):795-805
references: 17031648
references: Cancer Res Treat. 2007 Dec;39(4):139-49
references: 19746208
references: Oncology. 1995 May-Jun;52(3):182-8
references: 7715901
references: Diagn Pathol. 2008 Oct 22;3:41
references: 18945356
references: Cancer Res. 1990 Dec 15;50(24):8002-9
references: 1979253
references: EMBO J. 1993 Jun;12(6):2369-75
references: 8099545
references: Ann Surg. 1998 Oct;228(4):449-61
references: 9790335
references: Nihon Ika Daigaku Zasshi. 1998 Oct;65(5):358-66
references: 9808988
references: N Engl J Med. 1999 Mar 25;340(12):908-14
references: 10089184
references: N Engl J Med. 2008 Jul 31;359(5):453-62
references: 18669424
references: Pathologe. 2010 May;31(3):208-17
references: 20443098
references: ScientificWorldJournal. 2012;2012:941259
references: 22645475
references: J Surg Oncol. 2002 Oct;81(2):59-62; discussion 62
references: 12355403
references: J Clin Oncol. 2007 Jan 1;25(1):118-45
references: 17159189
references: Mol Cytogenet. 2011 Jun 20;4(1):14
references: 21689422
references: J Clin Oncol. 2004 Jun 1;22(11):2069-77
references: 15082726
references: Ann R Coll Surg Engl. 1998 Jan;80(1):16-24
references: 9579122
references: Oncology. 1998 Sep-Oct;55(5):475-81
references: 9732228
references: Br J Surg. 2007 Mar;94(3):263-4
references: 17318802
references: Cancer Res. 1991 Feb 1;51(3):1034-8
references: 1670998
references: N Engl J Med. 2001 Mar 15;344(11):783-92
references: 11248153